trending Market Intelligence /marketintelligence/en/news-insights/trending/egyx-d71tb3tq95ep4qkjq2 content esgSubNav
In This List

Luye Pharma to develop CAR-T therapies with Elpis Biopharmaceuticals

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Luye Pharma to develop CAR-T therapies with Elpis Biopharmaceuticals

China's Luye Pharma Group Ltd. entered a collaboration and license deal with privately held Elpis Biopharmaceuticals Corp. to develop novel anticancer therapies.

The partnership will focus on discovery and development of dual-target chimeric antigen receptor T-cells, or CAR-T cell, therapies and biologics — medicines derived from living organisms.

Financial terms of the deal were not disclosed.

Under the deal, Boston-based biotech Elpis will develop the CAR-T candidates while Hong Kong-listed and Yantai, China-based Luye Pharma will be responsible for developing and commercializing the therapies in the Asian country.

The agreement builds upon a 2017 immuno-oncology and immune-cell therapy collaboration between the companies. The most advanced CAR-T cell therapy drug under the collaboration is in a preclinical study stage, Luye Pharma said in the press release.

CAR-T cell therapies work by manipulating a patient's own disease-fighting T cells and then infusing them back into the body to fight blood cancers.

SNL Image